INTRODUCTION
Motivated by the rapidly expanding incidence of cancer, the US government established the cooperative cancer group network under the aegis of the National Cancer Institute (NCI) in 1955. 1 The rationale for forming large, multi-institutional groups was based on the growing recognition that cancer represented a taxonomy of clinically and pathologically diverse malignant processes. 2 To develop effective therapies, it would be necessary to test a variety of treatments on diverse populations. This required a large number of subjects with identical cancers. To accrue a sufficient number of patients, cancer centers had to pool their resources. A distinction of the cooperative groups was that all centers adhered to rigid and well-defined protocols that strengthened the findings of the clinical trials. As a prototype, the cooperative cancer group networks within the United States greatly expanded in the ensuing decades, and served as a model for collaborative research in Europe and Canada.
As the concept of the cooperative cancer group networks continued to evolve, there was a push to focus on specific modes of cancer therapeutics. In 1972, Dr. Simon Kramer argued that radiation therapy, which was emerging as a curative modality in the management of neoplastic disease, required a cooperative group mechanism of its own to properly assess its efficacy. 3 As a result of the pioneering efforts of Kramer and his colleagues, the Radiation Therapy Oncology Group (RTOG) was founded. The RTOG has been among the most successful entities within the NCI constellation of cooperative groups. The success is manifest by an increasing annual accrual of patients, a steady expansion of centers affiliated with the group, a broadening of the number of disease sites studied, and a decrease in the median time required to complete studies. [4] [5] [6] In a groundbreaking paradigm shift, in 2004, the Membership Committee of the RTOG adopted a proposal that would make global expansion of RTOG activities a strategic priority. After approval by the Steering Committee of the RTOG, a tender inviting foreign centers (outside North America) to apply for affiliate membership was issued. Acceptance was contingent on the candidate center's ability to document adherence to the guidelines specified by the RTOG. 7 Affiliate membership was granted to Tel Aviv Medical Center (TAMC; Tel Aviv, Israel) in 2005. Subsequently, centers from Peru, South Korea, and Australia were invited to join the RTOG. This article will discuss the basis for globalization of the RTOG's clinical programs and enumerate the benefits associated with expanded international membership from the perspective of both the RTOG and the international affiliates ( Table  1) . The inclusion of non-US centers was not without challenges, and the experiences of one of the affiliates (TAMC) to meet the requirements set forth by the RTOG will be discussed.
RTOG AND GLOBALIZATION
In 1971, then-President Richard Nixon and the US Congress declared war on cancer. In the State of the Union address of that year, Nixon argued for a national commitment in the fight against cancer, commenting that, "America has long been the wealthiest nation in the world. Now it is time we became the healthiest nation in the world." Given this somewhat nationally self-centered goal, it would seem that the expansion of the RTOG to include foreign centers would run counter to this aim. Dispensing limited funds to nondomestic institutions means that there is less available to cancer centers in the United States. More to the point, money spent on treating foreigners is money not spent on treating US residents. Altruism may and should be part of the motivation of expanding clinical research beyond the borders of the United States.
8 However, it is one thing for the United States Centers for Disease Control to do onsite research and donate much needed anti-HIV medications and research support to African countries as part of ongoing clinical research programs, 9 and a totally different undertaking to recruit foreign nationals to participate in US-based clinical research and subsidize their treatment.
The decision of the RTOG to recruit international members was motivated by a pragmatic approach related to cancer research. The war on cancer needs to be waged on many fronts, and the outcome of this war, similar to other wars, will most likely be determined by the number of resources that can be brought to bear in the battle against this modern-day scourge. The heterogeneity of cancer was already thought to be complex in the 1950s, and today, with more advanced understanding of cancer genetics and aberrant signal transduction, it is axiomatic that single-agent approaches will be inadequate against malignant disease. Multimodal treatment (eg, chemotherapy, surgery, and radiotherapy) is now the rule, and the challenge for clinical cancer research is to find the right balance of the constituent therapies. In practical terms, this means that more studies involving larger and diverse populations need to be performed.
For cooperative cancer groups to maintain a leadership role in clinical cancer research, they would have to activate more protocols, accrue a larger number of patients, and accelerate turnaround time so that more protocols could be executed. Even so, the capacity of the cancer groups would be exceeded if the number of centers was not increased. The leadership of the RTOG recognized that, to attain such goals, expansion should be done both domestically and internationally. Previous limitations on international expansion such as geographic distance and differences in medical practice have been ameliorated with improved global communications that facilitate not only data transmission but also international harmonization of clinical practice and investigational drug development.
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There were other motives behind the RTOG's effort to recruit international centers. Extensive clinical cancer research is currently being conducted in numerous countries. As a result, there is duplication of studies, which leads to the wasting of scarce fiscal resources. Imperfect duplication of protocols and nonuniform standards can have an impact on research findings. For example the treatment of carcinoma of the cervix was stagnant for a prolonged period of time as clinician-scientists struggled to agree on the optimal synthesis of external-beam irradiation, brachytherapy regimens, and chemotherapy as reflected by the lack of uniformity among study protocols.
14 With discrepant results, it is difficult for clinicians and/or patients to decide whether a specific treatment modality is appropriate. Without the resources and the commitment to quality control that have been the hallmark of the RTOG, positive or negative findings of specific studies might not meet the strict requirements demanded by evidence-based medicine, with the possibility of tragic consequences if scientifically unfounded therapies are disseminated. Consideration also has to be given to the protection of human subjects involved in studies. Indeed, in a policy statement adopted by the American Society of Clinical Oncology (ASCO) in 2002, it was advocated that the protection afforded to participants in US-based trials be extended to subjects recruited for international, multi-institutional clinical trials, and that this can best be done in the framework of foreign institutions' joining the cooperative cancer groups. 15 The inclusion of more centers and patients with diverse ethnic, socioeconomic, and cultural backgrounds would only strengthen the conclusions of a given study. With more centers, there is less chance of bias affecting the result. Unduly favorable results from one center will not disproportionately affect the results of a trial, and the larger number of patients will allow for the use of multiple end points that supplement the main finding and offer a greater chance for obtaining statistically significant results and avoiding type 2 errors because of insufficient numbers of enrollees. Moreover, the addition of centers allows for a faster rate of accrual and the chance to systematically study rare cancers.
Beyond the requirement for greater and more rapid accrual of patients which frankly could be accomplished by recruiting more centers in North America, there is a need to expand the patient base to International center Upgrade of medical standards for patients enrolled on study with "spillover effect" to non-participants
Nonreimbursable management expenses
External review and quality assurance from an established entity Provision of medication without charge RTOG Expanded "N" empowers clinical trials Need to dispatch reviewers to foreign country Accelerated accrual Verification of applicability of intervention being tested Increased probability of adoption of clinical intervention include individuals from different ethnic backgrounds who are exposed to a variety of environmental factors (eg, diet, climate, pollutants, and so on) that could have an impact on outcome. There is also a greater appreciation of the role that genetics of the host (eg, pharmacogenomics) has in determining susceptibility, prognosis, and response to treatment, and these factors can best be analyzed through evaluation of a diverse population. 16, 17 With a more varied pool of patients, study results would have greater universality and applicability.
Foreign centers also have strong motivations to align themselves with the RTOG. Smaller countries may not have the patient numbers to execute either institutional studies or collaborative national studies. By joining the RTOG, they can contribute to large-scale studies while simultaneously benefiting from the data derived from these clinical trials. In following the identical protocols used by the RTOG, study results are more meaningful because the experimental conditions are uniform at all sites. At another level, participation in the RTOG requires adhering to high quality control standards and making data available for external audits. Patients receiving care at an RTOG affiliate, even if they are not enrolled in a specific protocol, can be assured that they are receiving a high level of care. Finally, individuals with cancer are afforded a chance to receive cutting-edge therapy that might not otherwise have been accessible to them, either because of the costs of treatment or the lack of availability of certain experimental drugs or equipment.
CHALLENGES FACING FOREIGN INSTITUTIONS: A CASE STUDY
Despite the benefits of belonging to the RTOG, foreign radiotherapy centers face considerable challenges in meeting the standards set forth by the RTOG for affiliate membership (Fig 1) . These include bearing the costs involved in fulfilling RTOG prerequisites, changing clinical practices, and adopting institutional practices such as institutional review board (IRB) procedures so that they are compatible with the human-experimentation practices of the RTOG. Language barriers can be a major hurdle because patient documentation must be prepared in a language that can be understood by RTOG representatives. Likewise, primary documents written in the vernacular of a foreign institution must be translated to English so that monitoring can be carried out by the RTOG. In the following section, we will describe the challenges faced by TAMC and how these hurdles were surmounted en route to joining the RTOG. The experiences of TAMC will be useful to other centers outside North America seeking to join the RTOG and demonstrate the benefits associated with broadening participation in the RTOG.
TAMC AND THE RTOG: THE INSTITUTE OF RADIOTHERAPY AT TAMC
TAMC is one of the primary teaching affiliates of the Tel Aviv University School of Medicine, and one of the largest inpatient facilities in Israel. TAMC has a longstanding tradition of clinical and basic research and has been a participant in several European consortia such as the European Organisation for the Research and Treatment of Cancer (EORTC) and the Breast International Group (BIG). The Institute of Radiotherapy at TAMC has been operational for more than three decades and is now equipped with four linear accelerators, two computed tomography simulators, and capabilities for radiosurgery, brachytherapy, intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy. On average, 170 patients with varied primary tumors are treated daily with either curative or palliative intent. The strategic decision by TAMC to apply for RTOG membership was primarily motivated by the desire to introduce standards practiced by the RTOG and other cooperative cancer groups into the Israeli oncologic community. By accepting the clinically rigorous standards of the RTOG, it would be expected that not only patients enrolled into RTOG protocols but also those who declined to participate in these protocols or simply were deemed protocol-ineligible would derive benefit from the enhanced standard of care.
MEETING THE REQUIREMENTS FOR RTOG MEMBERSHIP
The RTOG has established a set of prerequisites that must be met by institutions to be considered for membership. Although the details are enumerated on the RTOG website, 7 several key requirements are worth noting here in more detail. First, the physics staff must submit a description of all equipment (eg, linear accelerators and simulators and their characterizing features), software, calibration schedule, and quality-assurance protocols. Second, physicians must provide a synopsis of all "clinical material" encountered (eg, number and type of patients seen in consultation, quantification of total fields treated per day, brachytherapy applications, and special procedures such as hyperthermia and radiosurgery). Third, all potential investigators (eg, physicians, physicists, clinical research associates) must complete the online course for the Human Participant Protections Education for Research Teams, which is sponsored by the National Institutes of Health (NIH; Bethesda, MD). 18 To meet the prerequisites set forth by the RTOG, TAMC began a comprehensive overhaul of its practices RTOG assessment that involved credentialing, translation of clinical materials, procedures for processing clinical specimens, data handling, internal review monitoring, instituting changes in indemnification and informed consent for patient participation, as well as the development of funding sources.
Credentialing
One of the challenges facing foreign institutions is ensuring that both study personnel and equipment meet the requirements of the RTOG. There are often differences between the United States and other countries in terms of specialty training and certification. Standards of care vary, and protocols for maintenance of machinery may not be sufficiently strict. To ensure that both TAMC personnel and equipment met RTOG standards, an extensive credentialing process was instituted. Institutional registries were accessed to determine the absolute number of cancer cases treated per year and to categorize the cases according to disease site and as a function of therapeutic intent (definitive v palliative). Case logs were solicited from physicians to establish the number of patients treated by each attending radiation oncologist on an annual basis. The availability of modern apparatus (eg, simulators, linear accelerators) and updated software (eg, treatment planning packages, record and verify systems) were documented. Phantom measurements and individualized test cases of novel procedures (eg, radiosurgery, partial breast irradiation) were submitted separately for review to the physics staff of RTOG. The latter were transmitted electronically to expedite the credentialing process and reduce expenditure.
Compliance With Cancer Therapy Evaluation Program Guidelines for International Collaborating Institutions
The NCI Cancer Therapy Evaluation Program (CTEP) has developed guidelines for international institutions wishing to participate in cooperative study groups. These guidelines, which are available online (http://ctep.cancer.gov/guidelines/nci_clin_intl_guidelines .pdf), detail specific requirements regarding protection of human subjects, uniform handling of data, protocol development, appropriate conduct of the trial, investigational drug handling, and external auditing. For institutions such as TAMC, in which participation in the RTOG involves receiving federal funds for per-case reimbursement, the requirements are particularly stringent. For example, TAMC must maintain a Federalwide Assurance (FWA) for the protection of human subjects indicating that they are complying with the guidelines established by the Office of Human Research Protection (OHRP) for institutions in countries other than the United States. Use of investigational new drugs (INDs) or commercially supplied trial drugs also is covered by CTEP and the US Food and Drug Administration regulations. The NCI has recommended that international centers establish an international source and distributor for INDs or commercial agents. This has proven challenging because it often requires the cooperation of pharmaceutical firms that, for various reasons (eg, liability, costs, proprietary interests), may be reluctant to supply study drugs.
The CTEP strongly recommends that the NCI-sponsored collaborative group (in this case, RTOG) identify a principal investigator at the foreign site who is responsible for effecting on-site protocol regulatory approval. The principal investigator also assumes responsibility for all protocol patient accruals, delivery of protocol treatment, and reporting of protocol-related toxicity and clinical data. In the case of TAMC, the task of bringing the Institute of Radiotherapy into compliance with CTEP guidelines and recommendations was facilitated by the fact that the principal investigator previously held leadership roles in the RTOG.
Language Barriers
Barriers need to be overcome where English is not the primary language. In Israel, all RTOG documents including protocols, consent forms, and patients' materials had to be translated into Hebrew. This is often a difficult task, especially with regard to informed consent because nuances in the translation regarding risks and benefits could lead to misunderstandings and impair the informed-consent process. Fortunately, many of the ancillary materials (eg, quality-of-life tools) had already been translated into Hebrew (as well as multiple other languages) and validated within the vernacular. To ensure appropriate informed consent, provision had to be made for interpreters who would translate the informed consent form containing the description of the study. In addition, patient documentation (eg, operative notes, imaging reports, pathologic diagnoses) was translated from Hebrew to English so that RTOG auditors would be able to verify the legitimacy of the cases enrolled onto specific protocols.
Clinical Specimen Handling
A unique hurdle associated with RTOG membership involved the handling of clinical specimens, especially tissue blocks. Tissue blocks have become a precious resource in the era of translational research because they can be processed to determine the impact of biologic markers on patient outcome. At present, all of the brain tumor protocols of the RTOG mandate submission of tissue blocks as a prerequisite for protocol enrollment. No precedent existed, however, in the Israeli health care system for the extramural transfer of human materials. To join the RTOG, the TAMC Institute of Radiotherapy had to obtain permission for tissue transfer from the TAMC IRB (Helsinki Committee), the national IRB, and the Israeli Ministry of Health. One difficulty encountered during the process was the insistence by the IRBs that separate applications be made for individual protocols, which represents a significant time expenditure (a three-step process that must be performed serially rather than in parallel) and can cause a delay in patient recruitment for new protocols.
Internal Review
A hallmark of large collaborative studies by the NIH is the requirement for external review and auditing. To prevent external audit failures, a rigorous internal review system had to be instituted. This involved weekly meetings with required attendance of physicians (radiation oncologists, medical oncologists, surgeons), physicists, clinical pharmacists, and clinical research associates. In addition to prophylaxing against audit failure, these meetings provide a forum for the review of interval progress on a per-patient basis, debugging of logistical obstacles, and refinement of strategic goals (eg, activating new protocols, terminating old protocols).
Indemnification
Responsibility for the adverse effects of therapeutic RTOG protocol-based interventions is borne by the treating institution. To minimize both the exposure of TAMC personnel and the RTOG to litigation, attorneys representing the hospital and the RTOG worked together to ensure that the appropriate waivers were enforceable.
Data Handling
As of late, information technology is playing a larger role in the RTOG and other cooperative cancer groups. Patient data, even information not currently required by the RTOG, needed to be recorded in a systematic fashion that would allow for easy transferability to existing RTOG databases. As mentioned earlier herein, CTEP has also established uniform methods for data recording and reporting that must be followed by all participating collaborative group centers. Databases used for the study had to be designed for forward compatibility in case the RTOG adapts new database software.
Funding
As stated in the introduction, there are numerous advantages for a non-North American center's allying itself with the RTOG. However, a major drawback is the cost of membership. The rigorous standards of the RTOG, the need for an extensive infrastructure for data management and record keeping, long-term patient tracking and follow-up, the costs of treatment, and the increased labor costs (physicians, technologists, allied health personnel) make membership in the RTOG an expensive proposition for any potential applicant whether in the United States or abroad. In the case of TAMC, it was necessary for the Institute of Radiotherapy to hire two additional data managers, a half-time medical secretary, and a nurse. In addition, the Institute's medical administrator devotes 0.125 of his time to RTOGrelated procedures. Moreover, physician time per RTOG patient is greater, so participating physicians had to reduce their patient loads.
The allocated RTOG reimbursement per protocol can defray some of the costs inherent in the upkeep of an RTOG center, but this reimbursement falls far short of covering the expenses encountered and the expected costs accrued over the lifetime of a protocol. For TAMC to join the RTOG, it was necessary to aggressively seek and secure funding from a variety of sources that include seed money invested by the TAMC administration and solicitations of philanthropic foundations. Our experiences are not unique, and the cost issues that behoove procurement of external funding will remain a significant challenge for any institute wishing to join the RTOG.
ACCEPTANCE INTO THE RTOG
In August 2005, the TAMC Institute of Radiotherapy was accepted into the RTOG. Since joining the RTOG, the Institute of Radiotherapy has devoted significant resources to initiating and maintaining RTOG protocols as described in the following sections. Currently, a network of nearly a dozen physicians participate in the recruitment and management of RTOG patients at TAMC. On a weekly basis, four to six physicians (along with pharmacists, physicists, and research associates) participate in "RTOG Rounds." Medical and surgical oncologists are invited to these meetings, and RTOG protocols and cases are discussed at institutional-wide tumor boards and grand rounds. To encourage participation of all oncologic disciplines in RTOG-related studies, the Institute of Radiotherapy has provided subsidies to enable health care professionals to attend RTOG-sponsored meetings and workshops.
Selection of Feasible Research Targets
In surveying the clinical caseload at TAMC, it was clear that the two most potentially fertile opportunities for accession of patients were tumors of the breast and brain. Accordingly, protocols pertaining to these disease sites were the first to be submitted to the institutional Helsinki committee. This decision was deliberate because it was readily apparent that the Helsinki committee could not be inundated by multiple submissions of RTOG protocols. Moreover, it was understood that the learning curve for protocol participation could be more confidently ascended by staff members (physicians, data managers, research nurses, and so on) if only a limited number of studies were being managed simultaneously. Similar logic was applied to the technologies selected at the outset. To wit, although TAMC possessed a full complement of the resources needed to execute protocols predicated on IMRT and adaptive treatment approaches, the decision was made to concentrate on the more straightforward protocols (eg, conformal treatment, palliative treatment) so as not to confound the goal of efficient protocol enrollment and acquisition of momentum. Conversely, because a brisk radiosurgery program was extant at TAMC, RTOG trial 03-20 (brain metastases from primary lung cancer treated with whole-brain irradiation, radiosurgical boost, and varying chemotherapies) was activated.
Enrollment of Patients Onto RTOG Studies
Approval for accrual to five RTOG protocols (three brain protocols; one breast protocol; one lung protocol) was granted by the Helsinki Committee in the latter part of 2005. During the course of the ensuing calendar year, 28 patients were enrolled onto these respective studies. Ten patients had breast cancer, and three had primary nonsmall-cell lung cancer. The remainder suffered from malignancies of the CNS. The 28 patients who enlisted ranked TAMC fourth in the standing of the 213 "affiliate members" of the RTOG (Table 2 ). Figure  2 shows a steady increase in the rates of accrual observed at TAMC during the first year and a half of active recruitment. Within the initial 
Compliance With Groupwide Standards
In February 2007, a random audit was conducted on seven of the aforementioned patients. This exercise did not require the actual dispatching of auditors from RTOG headquarters in Philadelphia, PA, but rather consisted of data exchange by electronic and postal mail. The parameters assessed (Table 3) pertained to the IRB monitoring, the informed consent process, the management of the investigative agents studied, and a review of actual patient case material. In each of the cases, no major violations were seen. Minor deviations from protocol guidelines were easily remedied.
DISCUSSION
As part of its agenda, the cooperative group mechanism was designed to serve as a model for cancer clinical trials throughout the world. From the outset, the leaders of the NCI recognized the limitations of single institutions, irrespective of size, to consistently accrue adequate patient numbers for the conduct of trials that would answer meaningful questions. Subsequently, leaders of the NCI advocated the fostering of greater international cooperation to speed technology transfers. 1 The internationalization of participants within the RTOG is thus in synchrony with the strategic expansion of the cooperative group system. TAMC has directly benefited from its affiliate membership in the RTOG by adopting the group's rigorous standards for administering radiotherapy, 19 calibration and dosimetry, 20 as well as quality assurance. 21 There has been a commensurate enhancement in quality of care among those patients who have enrolled onto RTOG trials. Moreover, the guidelines established by the RTOG have extended beyond the requirements of clinical investigation, and have found application in the daily practice conducted at TAMC. In fact, the major enticement to joining the RTOG lay in the mandatory adoption of a set of quality-assurance guidelines set by the group that could then also be applied to nonprotocol treatments. The RTOG standards, which are reflective of a national consensus within the United States, were utilized to raise the level of radiation treatment in Israel. The measure of success of these efforts can be judged by the fact that other radiation oncology centers in Israel are now exploring the possibility of affiliating with the RTOG.
The cooperative cancer groups are rapidly evolving to ensure their place at the forefront of the conduct of clinical trials during the 21st century. Incorporation of foreign centers will directly solidify the standing of the cooperative groups while simultaneously upgrading the clinical care administered to patients worldwide. Although it is too soon to determine whether the addition of international sites will accomplish all the goals described in this discussion, it is clear that the globalization of cooperative cancer group trials will maintain the United States' leadership position in clinical cancer research and bring about improved care and better decision making for patients, clinicians, researchers, and policy makers in the United States and abroad. 
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